RenovoRx (Nasdaq: RNXT)
Biotechnology ResearchCalifornia, United States11-50 Employees
RenovoRx is a California-based biotechnology company pursuing targeted oncology therapies and commercializing RenovoCath, a local drug-delivery device. Its Trans-Arterial Micro-Perfusion platform aims to deliver treatment directly to the arterial region near a tumor, providing high local exposure while potentially reducing systemic toxicity compared with traditional intravenous therapy. This approach seeks to improve safety, tolerability, and efficacy for cancer patients and supports targeted delivery of diagnostic and therapeutic agents. The company is evaluating its drug-device candidate, intra-arterial gemcitabine delivered via RenovoCath (IAG), in a Phase III trial for locally advanced pancreatic cancer, under FDA regulation. In addition to its clinical program, RenovoRx is actively commercializing RenovoCath as a standalone device, reporting its first commercial purchase orders in December 2024 and ongoing uptake at several major medical centers, including high-volume cancer centers. RenovoRx operates from Mountain View, California, and remains a relatively small enterprise focused on advancing its TAMP technology and related products.
1-888-653-2347 
support@leadiq.com 
